Home Tags License agreement

Tag: license agreement

Seattle Genetics and Immunomedics Terminate License Agreement for Sacituzumab Govitecan

Seattle Genetics and Immunomedics today confirmed that they have terminated their Exclusive Global Licensing Agreement for sacituzumab govitecan (IMMU-132), Immunomedics breakthrough therapy candidate to...

Pfizer Exercises Options As Part of License Agreement with Philogen

Swiss-Italian Philogen, a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products, has confirmed that Pfizer has exercised options granted...

The Business of Bispecific Antibodies: Generating Focused Development Libraries

Bispecific antibodies (BsAb), widely used in the development of anticancer immunotherapy, are proteins capable of simultaneously binding two different epitops, on the same or...

Millennium/Takeda Exercises Commercial License Right for Fleximer Technology

Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited has exercised an option to license commercial rights for its first novel Fleximer® antibody-drug conjugate or ADC developed as part of their collaboration with Mersana Therapeutics, announced earlier this year.

X